GlobeNewswire

Roche’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition

Share
  • Systemic sclerosis (SSc) is a rare disease that affects about 2.5 million people worldwide
  • Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a progressive disease that can significantly impact lung function and can be life-threatening
  • In a global study, Actemra/RoActemra reduced the rate of progressive loss of lung function in people with SSc-ILD compared to placebo
  • The U.S. Food and Drug Administration previously granted Priority Review designation to Actemra/RoActemra for the treatment of SSc-ILD

Basel, 05 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the FDA for the treatment of the disease.

Systemic sclerosis (SSc), also known as scleroderma, is an often devastating autoimmune disease that worsens over time and has no cure. It occurs when the immune system malfunctions causing tissues of the skin and lungs to thicken and harden.1-3 SSc affects about 2.5 million people worldwide.4 Interstitial lung disease (ILD), which may occur in approximately 80% of SSc patients, causes inflammation and scarring of the lungs and can be life-threatening.5

“We are honored to offer the very first FDA-approved biologic treatment option to people living with systemic sclerosis-associated interstitial lung disease,” said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. “We worked closely with the FDA to evaluate Actemra/RoActemra’s impact on lung function in this setting. This milestone approval provides a much-needed new treatment option for people living with this rare, debilitating disease.”

The FDA approval is based on data from the focuSSced trial, a Phase III randomised, double-blind, placebo-controlled clinical trial of 212 adults with systemic sclerosis. Supportive information was also used from the faSScinate trial, a Phase II/III, randomised, double-blind, placebo-controlled study in patients with SSc. The focuSSced trial did not meet its primary endpoint of change from baseline to week 48 in the modified Rodnan Skin Score (mRSS), which is a standard outcome measure for skin fibrosis (the scarring or hardening of the skin) in SSc. There also was not a statistically significant effect on the primary endpoint of mRSS in the faSScinate trial.

However, in the overall population of the focuSSced study, patients treated with Actemra/RoActemra, as compared to placebo-treated patients, were observed to have less decline from baseline to week 48 in observed forced vital capacity (FVC), a common measure of lung function that assesses how much air can be exhaled, and percent predicted forced vital capacity (ppFVC), which compares the observed FVC to that expected for a healthy person of the same age, gender, race and height. FVC results were similar in the faSScinate study.


Of the 212 patients who were randomised into the focuSSced study, 68 patients (65%) in the Actemra/RoActemra arm and 68 patients (64%) in the placebo arm had SSc-ILD at baseline, as confirmed by a visual read of high resolution computed tomograph (HRCT) by blinded thoracic radiologists. Post-hoc exploratory analyses were performed to evaluate the results within the subgroups of patients with and without SSc-ILD. The ppFVC and FVC results in the overall population were primarily driven by results in the SSc-ILD subgroup. In that subgroup, patients in the Actemra/RoActemra group had a smaller decline in mean ppFVC than patients on placebo (0.07% vs. -6.4%, mean difference 6.47%), and a smaller decline in FVC compared to placebo (mean change -14 mL vs. -255 mL, mean difference 241 mL). The mean change from baseline to week 48 in mRSS in patients receiving Actemra/RoActemra compared to placebo was -5.88 vs. -3.77, mean difference -2.11.

The safety profile for Actemra/RoActemra through week 48 in the focuSSced study was comparable for SSc-ILD and SSc patients overall, and in both the focuSSced and faSScinate studies was consistent with the known safety profile of Actemra/RoActemra. The most common adverse events in patients treated with Actemra were infections. 

Actemra was previously granted Priority Review for this condition by the FDA. This designation is given to medicines that have the potential to provide significant improvements in the treatment, prevention or diagnosis of a disease. This is the sixth FDA approved indication for Actemra/RoActemra since the medicine was launched in the United States in 2010.

About the focuSSced Trial
The focuSSced (NCT02453256) study was a Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of Actemra/RoActemra versus placebo in people living with systemic sclerosis. Patients were randomised in a 1:1 ratio to receive weekly subcutaneous injections of 162 mg of Actemra/RoActemra or placebo during the 48-week, double-blinded, placebo-controlled period, followed by open-label Actemra/RoActemra 162 mg administered subcutaneously every week for another 48 weeks. Rescue treatment was allowed during the treatment period after 16 weeks for >10% ppFVC decline or after 24 weeks for worsening skin fibrosis.

The primary efficacy endpoint was change from baseline at week 48 in mRSS. Change from baseline in FVC at week 48 was a key secondary endpoint. Of the 212 patients who were randomised, 68 patients (65%) in the Actemra/RoActemra arm and 68 patients (64%) in the placebo arm had SSc-ILD at baseline, as confirmed by a visual read of high resolution computed tomograph (HRCT) by blinded thoracic radiologists. The mean ppFVC at baseline for patients with SSc-ILD identified by HRCT was 79.6% (median 80.5%). Post-hoc analyses were performed to evaluate results within the subgroups of patients with and without SSc-ILD. The results of the key FVC secondary endpoints support the effectiveness of Actemra/RoActemra in reducing the rate of progressive loss of lung function in SSc-ILD patients. However, as the trial did not provide evidence of an effect on the primary endpoint of mRSS, the estimated magnitude of effect on the FVC endpoints should be interpreted with caution and comparisons to results of other products and studies may be misleading.

About Actemra/RoActemra
Actemra/RoActemra was the first approved anti-IL-6 receptor biologic, and is available in both intravenous (IV) and subcutaneous (SC) formulations for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis (RA). Actemra/RoActemra can be used alone or with methotrexate (MTX) in adult RA patients who are intolerant to, or have failed to respond to, other disease-modifying anti-rheumatic drugs (DMARDs). In Europe, RoActemra IV and SC are also approved for use in adult patients with severe, active and progressive RA who previously have not been treated with MTX. Actemra/RoActemra IV and SC are also approved globally for polyarticular juvenile idiopathic arthritis (pJIA) and systemic juvenile idiopathic arthritis (sJIA) in children two years of age and older. Actemra/RoActemra SC is approved globally for giant cell arteritis (GCA), and Actemra/RoActemra IV is approved for the treatment of chimeric antigen receptor (CAR) T-cell-induced severe or life-threatening cytokine release syndrome (CRS) in people two years of age and older. Actemra/RoActemra was the first approved treatment for sJIA, GCA and CRS. Actemra SC is now approved in the U.S. for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). In addition to the above-mentioned indications, in Japan Actemra IV is also approved for the treatment of Castleman’s disease and adult Still's disease, and the Actemra SC formulation is approved for Takayasu arteritis. Actemra/RoActemra is part of a co-development agreement with Chugai Pharmaceutical Co., Ltd and has been approved in Japan since April 2005. Actemra/RoActemra is approved in more than 110 countries worldwide.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017. pii: S0140-6736(17)30933-9.
[2] Del Papa N, Zaccara E. From mechanisms of action to therapeutic application: A review on current therapeutic approaches and future directions in systemic sclerosis. Best Pract Res Clin Rheumatol. 2015; 29:756-69.
[3] Hao Y et al. Early Mortality in a Multinational Systemic Sclerosis Inception Cohort. Arthritis Rheumatol. 2017; 69(5):1067-1077.
[4] University of Michigan Health. What is Scleroderma. Accessed March 2, 2021. https://www.uofmhealth.org/conditions-treatments/rheumatology/what-scleroderma
[5] Khanna D, Tashkin DP, Denton CP, Lubell MW, Vazquez-Mateo C, Wax S. Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford). 2019 Apr 1;58(4):567-579.


Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Dr. Nicolas Dunant
Phone: +41 61 687 05 17

Patrick Barth
Phone: +41 61 688 44 86
Dr. Daniel Grotzky
Phone: +41 61 688 31 10

Karsten Kleine
Phone: +41 61 682 28 31
Nina Mählitz
Phone: +41 79 327 54 74

Nathalie Meetz
Phone: +41 61 687 43 05
Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67


Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com

Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: jon_kaspar.bayard@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
Dr. Lisa Tuomi
Phone: +1 650 467 8737
e-mail: tuomi.lisa@gene.com

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

CrossAmerica Partners LP Maintains Quarterly Distribution22.4.2021 22:30:00 CEST | Press release

•Quarterly distribution of $0.5250 per unit attributable to the first quarter of 2021 Allentown, PA, April 22, 2021 (GLOBE NEWSWIRE) -- CrossAmerica Partners LP Maintains Quarterly Distribution Quarterly distribution of $0.5250per unit attributable to the firstquarter of 2021 ALLENTOWN, PA (April 22, 2021) – CrossAmerica Partners LP (NYSE: CAPL) announced today that the Board of Directors of its general partner has approved a quarterly distribution of $0.5250 per unit attributable to the first quarter of 2021 (annualized $2.10 per unit). The distribution attributable to the first quarter is payable on May 11, 2021 to all unitholders of record on May 4, 2021. CrossAmerica will host a conference call on May 11th at 9:00 a.m. Eastern Time to discuss first quarter earnings results, which will be released after the market closes on Monday, May 10. About CrossAmerica Partners LP CrossAmerica Partners is a leading wholesale distributor of motor fuels, convenience store operator, and owner and

Interim Report January-March 202122.4.2021 18:30:00 CEST | Press release

First quarter 2021 Net profit for the first quarter amounted to MSEK 44.6 (-4.0).Earnings per share amounted to SEK 4.00 (-0.35).Net asset value amounted to MSEK 703 (SEK 63.04 per share) at March 31, 2021, compared to MSEK 679 (SEK 60.87 per share) at March 31, 2020.Net cash amounted to MSEK 180 (SEK 16.16 per share) at March 31, 2021, compared to MSEK 219 (SEK 19.65 per share) at December 31, 2020.The 2021 Annual General Meeting resolved to pay a dividend of 3.00 SEK per share for FY 2020. Comments by the CEO NAXS experienced a steady development during the first quarter of 2021 with the NAV/share increasing by 8.5%, including the dividend paid out. During the quarter, NAXS made a second co-investment alongside JAB Holding, this time in Krispy Kreme Doughnuts, the world-famous doughnut brand. As to the underlying funds, they acquired 4 new portfolio companies and signed or closed 4 exits during the quarter. In addition, a partial exit took place with the listing of Kreate on Nasdaq H

Prosafe SE: Supporting statement to the 2020 Annual Report in light of the ruling in the Westcon matter22.4.2021 18:30:00 CEST | Press release

Reference is made to Prosafe's annual accounts for 2020 published on 25 March 2021 as well as the notice for annual general meeting published on 12 April 2021. Reference is further made to announcement on 15 April 2021, in which Prosafe informed that the Gulating Court of Appeal had decided against Prosafe in the Westcon matter, thereby awarding full payment to Westcon of amounts claimed and thus reversing the ruling by the Stavanger District Court in the first instance. In light of the ruling, Prosafe has today issued a supporting statement to its 2020 annual report and accounts. The statement is attached. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com Stavanger, 22 April 2021 Prosafe SE For further information, please contact: Jesper K. Andresen, CEO Phone: +47 51 65 24 30 / +47 907 65 155 Stig Harry Christiansen, Deputy CEO

Delårsrapport januari – mars 202122.4.2021 18:30:00 CEST | Pressemelding

Första kvartalet 2021 Resultat efter skatt uppgick till 44,6 (-4,0) MSEK.Resultatet per aktie uppgick till 4,00 (-0,35) SEK.Substansvärdet uppgick till 703 MSEK (63,04 SEK per aktie) per den 31 mars 2021, jämfört med 679 MSEK (SEK 60,87 per aktie) per den 31 december 2020. Nettokassan uppgick till 180 MSEK (16,16 SEK per aktie) per den 31 mars 2021, jämfört med 219 MSEK (19,65 SEK per aktie) per den 31 december 2020.Årsstämman 2021 beslutade att lämna en utdelning om 3,00 SEK per aktie. VD-kommentar NAXS utvecklades positivt under första kvartalet och substanvärdet per aktie ökade med 8,5% inklusive lämnad utdelning. Under första kvartalet gjorde NAXS ytterligare en saminvestering parallellt med JAB Holding, denna gång i Krispy Kreme Doughnuts verksamt i USA. Vad gäller underliggande fonder förvärvade dessa 4 nya portföljbolag och undertecknade eller genomförde 4 exit under perioden. Vidare genomfördes en partiell exit genom börsnotering av Kreate på Nasdaq Helsingfors. NAXS lämnade un

Conagen’s Novel Solution to Making Natural Capsaicin by Fermentation Accessible22.4.2021 18:23:30 CEST | Press release

Bedford, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Scalable, sustainable capsaicin ingredients for its use in food, consumer and industrial products have now become more accessible. Conagen announced it has successfully scaled-up its fermentation process for the production of premium capsaicin and its related capsaicinoid molecules. Chili peppers are widely used as a food additive in spicy and hot cuisines, due to its hot and pungent characteristics. Consumers globally are demanding more clean, natural and exciting flavors, especially hot and spicy flavors. Yet, the challenge in meeting this demand is that capsaicin from chili peppers is difficult to use because of its hot properties, proposing challenges to manufacturers. Capsaicin extraction is limited by the availability of chili peppers, which is subject to fluctuations in price and quality. The market for capsaicin is growing because of its pungent characteristic, which is very versatile in a broad spectrum of applications, includ

OREGE: Annual results 2020 and outlook22.4.2021 18:05:00 CEST | Press release

PRESS RELEASE Voisins Le Bretonneux, 22 April 2021 – 6 PM ANNUAL RESULTS 2020 AND OUTLOOK ___________________________________________________________________ Summary financial information for the year ended December 31 2020. Strong growth in turnover which validates the commercial approach taken by Orege in recent years 15% decrease in net operating expenses, thanks to savings on the Group's fixed costs. (Consolidated financial statements approved by the board of directors on 21 April 2021. The audit procedures by the statutory auditors are being finalized.) In k€ - IFRS2020 2019 Turnover2 006935Net operating expenses:Payroll costs-3 334-3 814Operating expenses:Manufacturing, sub-contracting-980-1 816Travel and subsistence expenses-532-829Leasing and maintenance-431-460Other operating expenses-1 334-1 510Depreciation-511-54Amortization-744 -781 Total net operating expenses- 7 866- 9 264Operating loss-5 860-8 329Net financial loss-1 563-1 859Corporation tax--Net loss-7 423 -10 188 Turno

Wolters Kluwer Annual General Meeting of Shareholders adopts all resolutions22.4.2021 17:25:00 CEST | Press release

Wolters Kluwer Annual General Meeting of Shareholdersadopts all resolutions April 22, 2021 –Wolters Kluwer, a global provider of professional information, software solutions, and services,is pleased to announce that all resolutions were adopted as proposed at today’s Annual General Meeting. Reappointment of members of the Supervisory Board and member of the Executive Board Frans Cremers and Ann Ziegler were reappointed as members of the Supervisory Board and Kevin Entricken was reappointed as member of the Executive Board. The Supervisory Board members represent a diversity of nationality, experience, talent, and expertise. Three (43%) of the seven Supervisory Board members are female, in line with Dutch corporate governance standards and proposed legislation. 2020 Financial Statements and dividend Shareholders voted to adopt the Financial Statements for 2020 as included in the 2020 Annual Report and approved a total dividend of €1.36 per ordinary share, resulting in a final dividend o